PRESENTATION:  Dapagliflozin 5 mg /10 mg, Metformin 500mg

DRUG CLASS: SGLT2 Inhibitor and Bigaunides

MECHANISM OF ACTION:

By inhibiting sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubules, dapagliflozin reduces reabsorption of filtered glucose from the tubular lumen and lowers the renal threshold for glucose (RT ).

SGLT2 is the main site of filtered glucose reabsorption; reduction of filtered glucose reabsorption and lowering of RT result in increased urinary excretion of glucose, thereby reducing plasma glucose concentrations.

Dapagliflozin also reduces sodium reabsorption and increases sodium delivery to the distal tubule, which may decrease cardiac preload/afterload, downregulate sympathetic activity, and decrease intraglomerular pressure.

Metformin decreases hepatic glucose production, decreasing intestinal absorption of glucose and improves insulin sensitivity (increases peripheral glucose uptake and utilization)

INDICATIONS & DOSAGE: As Directed by the Physician